Majeti R, Park CY, Weissman IL. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood [J]. Cell Stem Cell, 2007;1(6):635-645.
[3]
Schittger S,Schoch C,Dugas M,et al.Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia:correlation cytogenetics,FAB subtype,and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease [J]. Blood, 2002, 100(1): 59-66
[4]
Boissel N,Renneville A,Biggio V,et al.Prevalence,clinical profile,and prognosis of NPM mutations in AML with normal karyotype [J]. Blood, 2005,106(10):3618-3620．
[5]
Schnittger S,Schoch C,Kern W,et al. Nucleophosmin gene mutations are predictors of favorable prognosis inacute myelogenous leukemia with anormal karyotype [J].Blood.,2005, 106(12): 3733-3729.
[6]
Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells [J]. Cell,2009,138(2): 286-299.
[7]
Tong WG, Sandhu VK, Wood BL,et al. Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia [J]. Haematologica,2014 Dec 19. pii: haematol.2014.118422. [Epub ahead of print]
[8]
Illmer T,Ehninger G.FLT3 kinase inhibitors in the management of acute myeloid leukemia [J]. Clin Lymphoma Myeloma,2007,8(Suppl 1):24-34
[9]
Zhang Q, Bai S, Vance GH. Molecular genetic tests for FLT3, NPM1, and CEBPA in acute myeloid leukemia [J].Methods Mol Biol, 2013,999:105-121.
[10]
Corbeil D, Roper K, Hellwig A, et al. The human CD133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions [J]. J Biol Chem,2003, 275(8):5512-5520.
[11]
Toren A, Bielorai Y, Jacob-Hirsch J. CD133-positive hematopoietic stem cell "stemness"genes contain many genes mutated or abnormally expressed in leukemia [J]. Stem cells, 2005, 23(8): 1142- 1153.
[12]
Kratz-Albers K, Zuhlsdorf M, Leo R, et al. Expression of CD133, a novel stem cell marker, on human leukemic blasts CD34- antigen and on human CD34? leukemic cell line: MUTZ-2 [J].Blood, 1998, 92(11):4485-4487.
[13]
Buhring HJ, Seiffert M, Marxer A, et al. AC133 antigen expression is not restricted to acute myeloid leukemia but is also found on acute lymphoid leukemia blasts and on a subset of CD34? B-cell precursors [J]. Blood, 1999,94(2):832-833.
[14]
Sharma RK, Purohit A, Somasundaram V,et al.Aberrant myeloid antigen co-expression is correlated with high percentages of CD34-positive cells among blasts of acute lymphoblastic leukemia patients: an Indian tertiary care center perspective [J].Blood Res, 2014,49(4):241-245.
[15]
Plasschaert SL, Kamps WA, Vellenga E, et al. Prognosis in childhood and adult acute lymphoblastic leukemia: a question of maturation? [J]. Cancer Treat Rev,2004,30(1):37-51.
[16]
Yunsuk Choi , Je-Hwan Lee, Sung-Doo Kim, et al. Prognostic implications of CD14 positivity in acute myeloid leukemia arising from myelodysplastic syndrome [J]. Int J Hematol, 2013, 97(2): 246-255.
